General Information of the Compound
| Compound ID |
CP0467073
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
(E)-N-[4-[(1-benzylindazol-5-yl)amino]-7-ethoxyquinazolin-6-yl]-4-[(2S,6R)-2,6-dimethylpiperazin-1-yl]but-2-enamide
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C34H38N8O2
|
||||||||||||||||||
| Molecular Weight |
590.732
|
||||||||||||||||||
| Canonical SMILES |
CCOc1cc2ncnc(Nc3ccc4n(Cc5ccccc5)ncc4c3)c2cc1NC(=O)\C=C\CN1[C@@H](C)CNC[C@H]1C
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C34H38N8O2/c1-4-44-32-17-29-28(16-30(32)40-33(43)11-8-14-41-23(2)18-35-19-24(41)3)34(37-22-36-29)39-27-12-13-31-26(15-27)20-38-42(31)21-25-9-6-5-7-10-25/h5-13,15-17,20,22-24,35H,4,14,18-19,21H2,1-3H3,(H,40,43)(H,36,37,39)/b11-8+/t23-,24+
Show/Hide
|
||||||||||||||||||
| InChIKey |
WJGBEIOIHHBCIV-RRSRKQOQSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00922, Epidermal growth factor receptor
Protein ID: PT01233, Receptor tyrosine-protein kinase erbB-2
Protein ID: PT01159, Receptor tyrosine-protein kinase erbB-4
Protein ID: PT00892, Tyrosine-protein kinase JAK3